Celcuity Inc
CELC78.390USD
+1.690+2.20%
交易中 （美东）报价延迟15分钟
3.05B总市值
亏损市盈率 TTM
关于 Celcuity Inc 公司
Celcuity Inc. 是一家临床阶段的生物技术公司，开发用于治疗多种实体肿瘤的靶向疗法。其主要治疗候选药物是 gedatolisib，这是一种强效的小分子可逆抑制剂，可选择性靶向所有 I 类磷脂酰肌醇-3-激酶 (PI3K) 亚型和两种雷帕霉素靶标 (mTOR) 亚复合物 mTORC1 和 mTORC2。其针对 gedatolisib 的初始临床开发计划专注于治疗激素受体阳性 (HR+)、人表皮生长因子受体 2 阴性 (HER2-) 或 HR+/HER2-、晚期或转移性乳腺癌患者以及转移性去势抵抗性前列腺癌患者。其 VIKTORIA-1 正在评估 gedatolisib 与氟维司群联合使用或不联合使用哌柏西利对 HR+/HER2- 晚期乳腺癌患者的疗效。其 CELsignia 伴随诊断平台能够分析活体患者肿瘤细胞，以识别新的癌症患者群体。
Celcuity Inc简介
公司代码CELC
公司名称Celcuity Inc
上市日期Sep 20, 2017
CEOMr. Brian F. Sullivan
员工数量87
证券类型Ordinary Share
年结日Sep 20
公司地址16305 36th Ave N Ste 100
城市MINNEAPOLIS
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编55446-4285
电话17633920767
网址https://www.celcuity.com/
公司代码CELC
上市日期Sep 20, 2017
CEOMr. Brian F. Sullivan
Celcuity Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.13M
+3.45%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.13M
+3.45%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月31日 周日
更新时间: 8月31日 周日
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
18.66%
BVF Partners L.P.
8.17%
Sullivan (Brian F)
7.38%
Soleus Capital Management, L.P.
7.10%
Perceptive Advisors LLC
6.29%
其他
52.40%
持股股东
持股股东
占比
Baker Bros. Advisors LP
18.66%
BVF Partners L.P.
8.17%
Sullivan (Brian F)
7.38%
Soleus Capital Management, L.P.
7.10%
Perceptive Advisors LLC
6.29%
其他
52.40%
股东类型
持股股东
占比
Hedge Fund
42.19%
Investment Advisor
19.98%
Individual Investor
11.21%
Investment Advisor/Hedge Fund
8.70%
Venture Capital
6.52%
Private Equity
6.33%
Research Firm
2.23%
Corporation
0.82%
Pension Fund
0.15%
其他
1.86%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
241
36.62M
86.31%
-4.48M
2025Q2
214
35.30M
87.21%
-4.75M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
7.92M
18.66%
+170.10K
+2.20%
Sep 08, 2025
BVF Partners L.P.
3.47M
8.17%
--
--
Jun 30, 2025
Sullivan (Brian F)
3.13M
7.38%
+104.34K
+3.45%
Sep 02, 2025
Soleus Capital Management, L.P.
3.01M
7.1%
+437.70K
+17.00%
Jun 30, 2025
Perceptive Advisors LLC
2.67M
6.29%
+1.04M
+63.52%
Jul 30, 2025
New Enterprise Associates (NEA)
2.14M
5.05%
-150.00K
-6.54%
Aug 18, 2025
The Vanguard Group, Inc.
1.67M
3.93%
-4.46K
-0.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.87M
4.4%
-157.82K
-7.79%
Jun 30, 2025
Eventide Asset Management, LLC
1.39M
3.27%
+123.77K
+9.78%
Jun 30, 2025
Laing (Lance G Ph.D.)
1.25M
2.95%
--
--
Mar 17, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
3.44%
Virtus LifeSci Biotech Clinical Trials ETF
2.84%
Invesco Dorsey Wright Healthcare Momentum ETF
2.32%
Tema Oncology ETF
1.6%
ALPS Medical Breakthroughs ETF
1.22%
Invesco Dorsey Wright SmallCap Momentum ETF
0.58%
iShares Micro-Cap ETF
0.28%
VictoryShares US Small Mid Cap Value Momentum ETF
0.17%
Vanguard US Momentum Factor ETF
0.12%
SPDR S&P Biotech ETF
0.1%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比3.44%
Virtus LifeSci Biotech Clinical Trials ETF
占比2.84%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.32%
Tema Oncology ETF
占比1.6%
ALPS Medical Breakthroughs ETF
占比1.22%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.58%
iShares Micro-Cap ETF
占比0.28%
VictoryShares US Small Mid Cap Value Momentum ETF
占比0.17%
Vanguard US Momentum Factor ETF
占比0.12%
SPDR S&P Biotech ETF
占比0.1%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
